# DSIP Half Life and Pharmacokinetics — What the Studies Show > DSIP half life is measured in minutes in animals, with no validated human pharmacokinetics. A cited reading of DSIP clearance, degradation, and why analogs were engineered to last longer. Born from sleep, gone in minutes — the clearance data, and what it forced researchers to do. ## The short version The DSIP half life is short — a matter of minutes, not hours. 'Half-life' just means the time it takes the body to clear half of a dose from the blood. For DSIP, animal studies put that window at only a few minutes, because enzymes and blood proteins break the little peptide down almost as fast as it appears. That single fact explains a lot. A molecule that vanishes in minutes is hard to study, hard to dose, and hard to turn into a reliable product — and there is no validated human pharmacokinetic profile for it at all. It is also why researchers have built modified, longer-lasting versions rather than using the natural peptide. This page reads the clearance data plainly and stays clear of any dosing instruction. ## What the DSIP half life data actually says The core measurement comes from a purpose-built enzyme immunoassay — a lab test built specifically to detect DSIP — used to track the metabolic clearance rate of the peptide given to dogs, with parallel work in monkeys and rats. It reported a very rapid plasma half-life on the order of only a few minutes, species-dependent, consistent with rapid enzymatic degradation [17]. In other words, the body removes DSIP almost as quickly as it enters the circulation, which is why building a reliable test for it was itself a piece of the research. Crucially, no validated human pharmacokinetic profile exists. The human DSIP studies measured *effects* — sleep, hormones — rather than a full concentration-versus-time curve, so the human clearance rate, distribution, and true half-life all remain uncharacterized. Any precise human half-life figure circulating online is not grounded in a validated human study; it is an estimate dressed as a measurement. The honest statement is the narrow one the animal data supports: in the species actually tested, DSIP clears in minutes [17]. ## Why it clears so fast DSIP is a short, unprotected peptide — nine amino acids with no built-in shield against the body's breakdown machinery. Plasma aminopeptidases (enzymes that snip peptides apart) and other proteins degrade it quickly, which is the mechanism behind the minutes-long half-life [17]. Short linear peptides are characteristically fragile this way, which is why the literature notes DSIP's susceptibility to rapid enzymatic degradation in plasma [7]. The naturally phosphorylated form, DSIP-P, and other synthetic structural analogs are reported to be more stable or potent in some assays — a direct response to the parent peptide's fragility [7]. There is a further wrinkle the literature flags: DSIP's activity depends on strict structural requirements, and its dose-response is parabolic, rising then falling as the dose climbs [7], so the usual assumption that a slow-clearing, higher-dosed peptide is a stronger one simply does not transfer here. The molecule's brevity in the body is not a side issue; it is central to why native DSIP has been so hard to develop into anything stable. ## A short half-life beside long-lasting effects Here is a puzzle the DSIP half life sharpens. If the peptide is gone from the blood in minutes [17], why did human and animal studies sometimes see effects that arrived late or lingered? In the 1981 human sleep study, the benefit did not appear at once — it surfaced in the second hour after the injection, well after the peptide itself would have cleared [2]. Community accounts go further, describing effects that felt delayed by hours or even into the next day. The literature does not fully resolve this, and this site will not pretend it does. A fleeting molecule producing a delayed effect suggests DSIP may act by triggering something downstream rather than by simply being present — but with no identified receptor and no validated human pharmacokinetics, that remains an open question, not a settled mechanism [3]. The mismatch between a minutes-long half-life and slower-feeling effects is one more strand of the unresolved DSIP riddle. ## What a short half-life means for the research A minutes-long half-life shapes everything downstream. It makes timing in the body fleeting, complicates any attempt to maintain a steady level, and helps explain the engineering turn in modern DSIP work. A 2024 study built a DSIP fusion peptide designed to cross the blood-brain barrier and reported it outperformed unmodified DSIP in an insomnia mouse model [6], and an earlier yeast-expressed DSIP fusion protein dose-dependently deepened drug-induced sleep in mice [15] — both efforts, in effect, to give the fragile peptide a longer, more useful life. It is worth being clear about what is *not* known. There is no validated human half-life, no human concentration-versus-time curve, and no established dosing interval grounded in human pharmacokinetics [17]. Any precise number quoted online for how long DSIP lasts in a person is extrapolated, not measured. The takeaway for any reader weighing the [DSIP research](/research) is simple: the native molecule's pharmacokinetics are thin and animal-bound, the human profile is absent, and that gap is itself part of the unresolved DSIP story. --- A nocturnal field guide to DSIP, the delta sleep-inducing peptide — the slow-wave findings drawn out where the studies show them, the missing receptor and the nights nothing happened left openly in the dark, with no clinic at the bedside and nothing here dosed, supplied, or sold.